Table 3—

Logistic regression analysis of predictors of purified protein derivative (PPD) screening offer and completion among human immunodeficiency virus (HIV)-infected patients*

CharacteristicsPPD screening offer#PPD screening completion
Subjects offered PPDSubjects not offered PPDOR95% CIp-valueSubjects completing PPDSubjects non-completing PPDOR95% CIp-value
Subjects n14451851209236
Years of education
 <6319(22.1)55(29.7)1.00256(21.2)63(26.7)1.00
 6–8682(47.2)92(49.8)1.680.99–2.84ns564(48.6)118(50.0)1.671.10–2.510.01
 >8444(30.7)38(20.5)1.550.86–2.78ns389(32.2)55(23.3)2.651.65–4.25<0.001
AIDS diagnosis
 No1315(91.0)160(86.5)1.001098(90.8)217(91.9)1.00
 Yes130(9.0)25(13.5)0.300.16–0.58<0.001111(9.2)19(8.1)1.360.75–2.46ns
Antiretroviral therapy
 No1015(70.2)132(71.4)1.00835(69.1)180(76.3)1.00
 Yes430(29.8)53(28.6)1.591.03–2.450.04374(30.9)56(23.7)1.491.01–2.180.04
  • Data are presented as n (%) unless otherwise stated

  • OR: odds ratio

  • CI: confidence interval

  • ns: nonsignificant

  • AIDS: acquired immune deficiency syndrome

  • *: Sex, age, origin, HIV transmission category, occupation, CD4+ cell count, time since first HIV-positive test, and clinical centres are included in the models

  • #: includes 1,630 patients for whom PPD screening was indicated

  • : includes 1,445 patients to whom PPD screening was offered